Počet záznamů: 1

Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?

  1. 1.
    0350402 - PSU-E 2011 RIV CH eng J - Článek v odborném periodiku
    Smržová, J. - Urbánek, Tomáš
    Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?.
    Kidney & Blood Pressure Research. Roč. 33, č. 5 (2010), s. 333-342 ISSN 1420-4096
    Výzkumný záměr: CEZ:AV0Z70250504
    Klíčová slova: Cinacalcet * Itching * Phosphate binders
    Kód oboru RIV: FE - Ostatní obory vnitřního lékařství
    Impakt faktor: 1.500, rok: 2010
    http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&ArtikelNr=317935&Ausgabe=254503&ProduktNr=224258

    The cost and effectiveness patterns in the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the Czech Republic are unknown. 52 dialysis patients from 17 centers were followed up in a multicenter prospective study of laboratory and clinical responses to 12-month cinacalcet treatment. Treatment patterns and cost (including phosphate binders, vitamin D, and cinacalcet) were evaluated. The mean s-Ca, s-P, Ca×P, and iPTH dropped significantly. The mean cinacalcet dose reached 44.1 ± 23.0 mg/day after 12 months. Itching intensity decreased significantly. The direct cost of daily SHPT treatment rose significantly from EUR 8.77 ± 9.59 to 20.62 ± 9.22. Cinacalcet decreased elevated s-Ca, s-P, Ca×P, and iPTH, alleviated itching, and significantly raised the SHPT treatment cost. A minority of patients reached K/DOQI targets, especially due to poor phosphate control caused by insufficient phosphate binder treatment, cinacalcet underdosing, and advanced SHPT.
    Trvalý link: http://hdl.handle.net/11104/0190417